Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12
Inflammatory Bowel Diseases · 13.06.2025 · 31 (6) · 1583-1594
DOI: 10.1093/ibd/izae229 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.09.2024. Verfasst von Alessandro Armuzzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Quality of Life, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Here, we evaluate the impact of etrasimod 2 mg QD on health-related quality of life (HRQoL) in patients with UC.
Methods
This post hoc analysis used data from the Phase 3 randomized controlled trials, ELEVATE UC 52 and ELEVATE UC 12. HRQoL measures included: Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Survey (SF-36), and Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis (WPAI:UC) completed at baseline, Week 12 (both trials), and Week 52 (ELEVATE UC 52 only). For IBDQ analyses, patients were stratified by prior exposure to biologics/Janus kinase inhibitors (JAKi) and baseline modified Mayo score (MMS; 4-6 or 7-9).
Results
Generally, significantly greater proportions of patients receiving etrasimod (N = 527) vs placebo (N = 260) achieved IBDQ remission (IBDQ total score ≥170) and IBDQ response (IBDQ total score increase from baseline ≥16), with significant improvement in all IBDQ domain scores at Week 12 and maintained through Week 52. Significant differences in IBDQ remission and IBDQ response rates between etrasimod and placebo were more consistent among biologic/JAKi-naive patients vs those who were biologic/JAKi-experienced and in those with baseline MMS 7-9 vs 4-6. Significant improvements were observed in several SF-36 domain and summary scores and WPAI:UC domain scores at Week 12 and Week 52.
Conclusions
Etrasimod 2 mg QD demonstrated significant and clinically meaningful improvements across multiple HRQoL measures, including WPAI, vs placebo. Clinical Trial Registration ClinicalTrials.gov: NCT03945188; NCT03996369
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IBD Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
- Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
- Formerly Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigacíon Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
- Pfizer AG, Zürich, Switzerland.
ORCID-Profile: Marc Fellmann, Marla C Dubinsky
Förderung
- Pfizer
Zitieren
APA
Armuzzi, A., Rubin, D. T., Schreiber, S., Panés, J., Fellmann, M., Bartolome, L., Gruben, D., Goetsch, M., Bhattacharjee, A., Chaparro, M., & Dubinsky, M. C. (2025). Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases, 31(6), 1583-1594. https://doi.org/10.1093/ibd/izae229
Vancouver
Armuzzi A, Rubin DT, Schreiber S, Panés J, Fellmann M, Bartolome L, et al. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases. 2025;31(6):1583-1594. doi:10.1093/ibd/izae229
BibTeX
@article{Armuzzi2025,
author = {Armuzzi, Alessandro and Rubin, David T and Schreiber, Stefan and Panés, Julian and Fellmann, Marc and Bartolome, Lauren and Gruben, David and Goetsch, Martina and Bhattacharjee, Abhishek and Chaparro, María and Dubinsky, Marla C},
title = {Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {6},
pages = {1583--1594},
doi = {10.1093/ibd/izae229}
}
EUVIMED